1 of 1
Story summary
- On March 18, 2026, lawmakers raised concerns about China's dominance in pharmaceuticals.
- Florida Republican Neal Dunn (R-Fla.) accused China of a strategic effort to control the pharmaceutical supply chain.
- John Moolenaar (R-MI), chair of the House Select Committee on China, warned that China is cornering essential medicines and biotech.
- Projections show China's pharmaceutical revenue could rise 50 percent by 2030, to $2.1 trillion.
